Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1996-12-06
1998-11-17
Jarvis, William R. A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
514561, 514563, A61K 3122, A61K 31195
Patent
active
058377301
ABSTRACT:
A glycine uptake antagonist is administered for augmenting NMDA receptor-mediated neurotransmission treating symptoms of psychosis and of schizophrenia.
REFERENCES:
patent: 4904681 (1990-02-01), Cordi et al.
patent: 5068412 (1991-11-01), Ohfune et al.
patent: 5086072 (1992-02-01), Trullas et al.
patent: 5179085 (1993-01-01), Bigge et al.
patent: 5187171 (1993-02-01), Cordi et al.
patent: 5260324 (1993-11-01), Cordi et al.
patent: 5428069 (1995-06-01), Skolnick et al.
Andreasen N (1989): The scale for the assessment of negative symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry 155 (suppl. 7):49-52.
Costa J, Khaled E, Sramek J, Bunney W Jr, Potkin SG (1990): An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics. J Clin Psychopharmacol 10:71-72.
D'Souza DC, Morrissey K, Abi-Saab D, Damon D, Gil R, Bennett A, Krystal JH (1995): Intravenous glycine and oral D-cycloserine effects on CSF amino acids, plasma hormones, and behavior in healthy humans: Implications for schizophrenia. Schiz Res 15:147, 1995.
Javitt DC and Zukin SR (1991): Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308.
Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP (1994): Amerlioration of negative symptoms in schizophrenia by glycine. Am J Psyciatry 151:1234-1236.
Johnson JW. Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature. 325:529-31, 1987.
Kay SR, Fizbein A, Opler LA (1987): The positive and negative syndrome scale (PANSS) for schizophrenia. Schiz Bull 13:261-276.
Leiderman Eduardo, Zylberman Ilana, Zukin Stephen R., Cooper Thomas B, Javitt Daniel C. (1986): Preliminary Investigation of High-Dose Oral Glycine on Serum Levels and Negative Symptoms in Schizophrenia: An Open-Label Trial. Biol Psychiatry 39:213-215.
Potkin SG, Costa J, Roy S, Sramek J, Jin Y, Gulasekaram B (1992): Glycine in the treatment of schizophrenia --theory and preliminary results, in Novel Antipsychotic Drugs. Edited by Meltzer HY. New York, Raven Press.
Rosse RB, Theut SK, Banay-Schwartz M, Leighton M, Scarcella E, Cohen CG, Deutsch SI (1989): Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. Clin Neuropharmacol 12:416-24.
Waziri R (1989): Glycine therapy of schizophrenia. Biol Psychiatry 1988,
Toth Eugene, Weiss Benjamine, Banay-Schwartz Miriam, Lajtha Abel (1986): Effect of Glycine Derivatives on Behavioral Changes induced by 3-Mercaptopropionic Acid or Phencyclidine in Mice. 11:1-8.
Guastella J, Brecha N, Weigmann C, Lester HA, Davidson N (1992) Cloning, expression, and localization of a rat brain high-affinity glycine transporter. Proc Natl Acad Sci USA 89:7189-7193.
Jackson DM, Johansson C, Lindgren L-M, Bengtsson A (1994) Dopamine receptor antagonists block amphetamine-and phencyclidine-induced motor stimulation in rats. Pharmacol Biochem Behav 48:465-471.
Liu Q-R, Lopez-Corcuera B, Mandiyan S, Nelson H, Nelson, N (1993) Cloning and expression of a spinal cord-and brain-specific glycine transporter with novel structural features. J Biol Chem 1993; 268:22802-22808.
Smith KE, Borden LA, Hartig PR, Branchek T, Weinshank RL (1992) Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. Neuron 8: 927-935.
Tanii Y, Nishikawa T, Hashimoto A, Takahashi K (1994) Stereoselective antagonism by enantiomers of alanine and serine of phencyclidine-induced hyperactivity, stereotypy and ataxia in the rat. J Pharmacol Exp Ther 269: 1040-1048.
Toth E, Lajtha A (1986) Antagonism of phencyclidine-induced hyperactivity by glycine in mice. Neurochem Res 11: 393-400.
Zafra F, Aragon C, Olivares L, Danbolt NC, Gimenez C, Storm-Mathisen J (1995) Glycine transporters are differentially expresses among CNS cells. J Neurosci 15:3952-3969.
LandOfFree
Treatment of negative and cognitive symptoms of schizophrenia wi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of negative and cognitive symptoms of schizophrenia wi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of negative and cognitive symptoms of schizophrenia wi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-884806